Search

everythinglearnresearchcommunity

for

Search:↓

DHT blockers like dutasteride can reduce beard thickness while improving scalp hair. Using minoxidil on the beard may help maintain its thickness.

Hair loss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.

Creatine does not increase DHT levels, but some report hair loss when using it, possibly due to other factors. The effects on hair loss vary individually, with no clear connection established.

Poor diet and lifestyle contribute to male pattern baldness. Treatments like Minoxidil, dietary changes, and lifestyle adjustments may help slow hair loss.

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

Having hair improves social interactions and treatment by others, with hair transplants and finasteride enhancing confidence and attractiveness. People often receive more positive attention after addressing hair loss.

In the Czech Republic, doctors are largely unaware of hair loss treatments beyond minoxidil, and finasteride is hard to obtain. Many users suggest buying treatments like finasteride and minoxidil from other countries or online.

Minoxidil alone is often insufficient for treating hair loss because it doesn't address the DHT-related cause. Combining it with finasteride, a DHT blocker, is generally more effective.

A 24 year old male struggling with the physical and mental effects of balding, being short, and having a micropenis. Suggested treatments include taking medications such as finasteride and minoxidil, lifting weights, and trying not to compare himself to others.

A user who underwent a hair transplant in Istanbul to reduce balding, and the discussion of various treatments such as finasteride and growth hormone for preventing further hair loss.

A 20-year-old is experiencing hair thinning and seeks advice on starting treatment and regrowing hair. They are considering using Minoxidil, finasteride, or RU58841.

The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.

Best future hair loss treatment discussed: verteporfin, kx-826, and GT20029. Verteporfin could potentially end baldness with scarless procedures.

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.

An 18-year-old is experiencing significant hair loss and is concerned about treatment options, including finasteride, minoxidil, and dutasteride, due to potential side effects and costs. They are also taking vitamins for deficiencies and considering alternatives like hair transplants or embracing the bald look.

Young men experiencing early hair loss and discussing treatments like Minoxidil, finasteride, and RU58841. Many share feelings of frustration and coping strategies, with some finding solace in treatments and mindset shifts.

A user's one-year progress in hair loss treatment using finasteride and minoxidil. The user shared their experience and advice, including adjusting the amount of sprays used based on individual needs and the importance of patience and positivity in the process.

User xEternex tries hair regrowth with daily broccoli sprouts, apple extract containing procyanidin b2, and microneedling. Others discuss potential issues with the experiment and share their experiences with vegetable consumption and hair growth.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.